17 related articles for article (PubMed ID: 22946345)
1. Epigenetic modulations in cancer: predictive biomarkers and potential targets for overcoming the resistance to topoisomerase I inhibitors.
Madkour MM; Ramadan WS; Saleh E; El-Awady R
Ann Med; 2023 Dec; 55(1):2203946. PubMed ID: 37092854
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of nedaplatin and irinotecan in patients with extensive small-cell lung cancer.
Oshita F; Sugiura M; Murakami S; Kondo T; Saito H; Yamada K
Cancer Chemother Pharmacol; 2013 Feb; 71(2):345-50. PubMed ID: 23124649
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancer.
Oshita F; Yamada K; Saito H; Noda K
Cancer Chemother Pharmacol; 2008 Aug; 62(3):465-70. PubMed ID: 17960380
[TBL] [Abstract][Full Text] [Related]
4. Feasible combination chemotherapy with nedaplatin and irinotecan for patients with non-small cell lung cancer and multiple high-risk factors.
Oshita F; Saito H; Yamada K
J Exp Ther Oncol; 2007; 6(3):251-6. PubMed ID: 17552365
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
[TBL] [Abstract][Full Text] [Related]
6. Nedaplatin and irinotecan in patients with large-cell neuroendocrine carcinoma of the lung.
Kenmotsu Y; Oshita F; Sugiura M; Murakami S; Kondo T; Saito H; Yamada K
Anticancer Res; 2012 Apr; 32(4):1453-6. PubMed ID: 22493385
[TBL] [Abstract][Full Text] [Related]
7. Nedaplatin and irinotecan for patients with recurrent small cell lung cancer.
Ohe M; Oshita F; Kenmotsu Y; Sugiura M; Murakami S; Kondo T; Saito H; Yamada K
J Exp Ther Oncol; 2012; 10(1):65-9. PubMed ID: 22946345
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review.
Miyamoto M; Takano M; Kuwahara M; Soyama H; Kato K; Matuura H; Sakamoto T; Takasaki K; Aoyama T; Yoshikawa T; Furuya K
Cancer Chemother Pharmacol; 2018 Jan; 81(1):111-117. PubMed ID: 29124328
[TBL] [Abstract][Full Text] [Related]
9.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
